Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin ii and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 1, 2013, Pages

  Herath, Chandana B ^a   Mak, Kai ^a   Burrell, Louise M ^a   Angus, Peter W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Hepatic fibrosis; Hepatic resistance; Renin angiotensin system; Vasodilatation

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; ENDOTHELIAL NITRIC OXIDE SYNTHASE; METHOXAMINE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HEMODYNAMICS; LIVER CIRRHOSIS; MALE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; IN SITU HYBRIDIZATION; LIVER; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; METHOXAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, BRADYKININ B2; VASOCONSTRICTOR AGENTS;

EID: 84871877360     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00163.2012     Document Type: Article

References (49)

1. Alemayehu A, Lock KR, Coatney RW, Chou CC. L-NAME, nitric oxide and jejunal motility, blood flow and oxygen uptake in dogs. Br J Pharmacol 111: 205-212, 1994.
2. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 285: G642-G651, 2003.
3. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000.
4. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394, 2003.
5. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691, 2006.
6. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523- 528, 1996.
7. Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo M, Padrissa- Altes S, Bintanel-Morcillo M, Ramalho F, Serafin A, Rimola A, Arroyo V, Rodes J, Rosello-Catafau J, Peralta C. Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury. Crit Care Med 36: 1256-1266, 2008.
8. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46: 937-942, 2005.
9. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res 70: 8319-8328, 2010.
10. Cusma-Pelogia N, Oliveira SF, Nigro D, de Carvalho MH, Scivoletto R, Fortes ZB. Endothelium inactivation in in vitro perfused vascular beds. Comparison of methods. J Pharmacol Toxicol Methods 29: 157-163, 1993.
11. Dharmani M, Mustafa MR, Achike FI, Sim MK. Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur J Pharmacol 561: 144-150, 2007.
12. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, Greco L, Rosa M, Fauler B, Bader M, Alenina N, Guatimosim S. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52: 542-548, 2008.
13. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 46: 948-952, 2005.
14. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290, 2005.
15. Fouty B, Komalavilas P, Muramatsu M, Cohen A, McMurtry IF, Lincoln TM, Rodman DM. Protein kinase G is not essential to NOcGMP modulation of basal tone in rat pulmonary circulation. Am J Physiol Heart Circ Physiol 274: H672-H678, 1998.
16. Gorelik G, Carbini LA, Scicli AG. Angiotensin 1-7 induces bradykininmediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 286: 403-410, 1998.
17. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290: H2417-H2423, 2006.
18. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28: 926-931, 1998.
19. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 45: 495-506, 2007.
20. Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, Tikellis C, Burrell LM, Angus PW. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol 297: G98-G106, 2009.
21. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 47: 387-395, 2007.
22. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90: 783-790, 2005.
23. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev CD002147: 2003.
24. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363, 2005.
25. Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin- (1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol 36: 109-117, 2000.
26. Jackson B, Cubela RB, Conway EL, Johnston CI. Lisinopril pharmacokinetics in chronic renal failure. Br J Clin Pharmacol 25: 719-724, 1988.
27. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111: 1806-1813, 2005.
28. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 46: 274-279, 2005.
29. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, Casley D, Crowley P, Sievert W, Burrell LM, Angus PW. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 117: 375-386, 2009.
30. Marangoni RA, Carmona AK, Passaglia RC, Nigro D, Fortes ZB, de Carvalho MH. Role of the kallikrein-kinin system in Ang-(1-7)-induced vasodilation in mesenteric arterioles of Wistar rats studied in vivo-in situ. Peptides 27: 1770-1775, 2006.
31. Mathie RT, Ralevic V, Burnstock G. Portal vascular responsiveness to sympathetic stimulation and nitric oxide in cirrhotic rats. J Hepatol 25: 90-97, 1996.
32. Minano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am 39: 681-695, 2010.
33. Neves LA, Williams AF, Averill DB, Ferrario CM, Walkup MP, Brosnihan KB. Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7). Endocrinology 144: 3338-3343, 2003.
34. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 54: 1790-1796, 2005.
35. Pinheiro SV, Simoes E, Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M, Santos RA. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490-496, 2004.
36. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes E, Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 4: 787-803, 2008.
37. Rockey DC. Vascular mediators in the injured liver. Hepatology 37: 4-12, 2003.
38. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284: H1985-H1994, 2003.
39. Santos RA, Haibara AS, Campagnole-Santos MJ, Simoes E, Silva AC, Paula RD, Pinheiro SV, Leite MF, Lemos VS, Silva DM, Guerra MT, Khosla MC. Characterization of a new selective antagonist for angiotensin-(1-7), D-pro7-angiotensin-(1-7). Hypertension 41: 737-743, 2003.
40. Santos RA, Simoes E, Silva A.C, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003.
41. Santos RAS, Passaglio KT, Pesquero JB, Bader M, Simoes E, Silva AC. Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 38: 660-664, 2001.
42. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez- Leite JI, Botion LM, Bader M, Alenina N, Santos RA. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57: 340-347, 2008.
43. Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 3: 125-137, 2007.
44. Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 11: 150-155, 2011.
45. Shimizu M, Wang QD, Sjoquist PO, Ryden L. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. J Cardiovasc Pharmacol 34: 78-81, 1999.
46. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28: 702-707, 2007.
47. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566, 2005.
48. Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 53: 273-282, 2010.
49. Tox U, Steffen HM. Impact of inhibitors of the renin-angiotensinaldosterone system on liver fibrosis and portal hypertension. Curr Med Chem 13: 3649-3661, 2006.